Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Blastoma includes all cancers caused by immature or developing cells in different tissues or organs of the body. The characteristics of these cancers are rapid growth and the possibility of spreading to other parts of the body. Alfa Cytology is a world leader in the development of cancer vaccines. With our extensive experience and advanced platform, we can provide the best vaccine development services for blastoma.
Ongoing trials and research plans are evaluating new therapies or drugs for different types of blastoma. These studies aim to optimize therapy methods, reduce therapy-related side effects, and improve the survival rate in different age groups and risk categories.
The occurrence of blastoma is driven by genetic mutations, which can disrupt the normal growth and differentiation of immature cells, leading to uncontrolled cell proliferation and ultimately leading to tumor formation. These mutations mainly affect key cellular pathways involved in cell cycle regulation, signaling cascades, and DNA repair mechanisms. There may be significant differences in the specific disease mechanisms of different types of blastoma, and research needs to be conducted in different categories.
Fig. 1 Immunosuppressive tumor microenvironment. (Bolun, Z., et al., 2023)
There are ongoing studies targeting multiple molecular targets and therapeutic strategies for various types of blastoma. Some common targets and therapies are shown below.
| Targets/Therapies | Description |
| Genetic pathways | Innovative development of new therapies targeting specific genetic changes and signaling pathways associated with the occurrence and progression of blastoma is underway. For example, ALK inhibitors in neuroblastoma or SHH pathway inhibitors in medulloblastoma. |
| Immunotherapy | Immune checkpoint inhibitors, CAR T cell therapy, and antibody therapy targeting tumor-specific antigens are becoming effective therapies for certain blastomas. |
| Differentiation therapy | Differentiation therapy refers to inducing the maturation and differentiation of blastoma cells through drugs such as retinoic acid derivatives or histone deacetylase inhibitors, to inhibit excessive cell proliferation, ultimately achieving the effect of slowing down tumor growth and improving prognosis. |
Vaccine-based immunotherapy is a promising approach in the field of cancer treatment, including certain types of blastoma. The focus of research on blastoma vaccines is to stimulate the immune system to recognize and target cancer cells, enhancing the body's ability to initiate anti-tumor responses.
Blastoma vaccines can be classified by biologics or antigen sources, such as nucleic acids, peptides, recombinant proteins, microbial vectors, autologous or allogeneic whole tumor cells, manipulated antigen-presenting cells (APCs), and other artificial systems.
Blastoma represents various malignant tumors originating from immature cells in different tissues. Alfa Cytology provides diversified Blastoma vaccine development services, including but not limited to the following.
Research on vaccine development, targeted therapy, and immunotherapy provides hope for improving prognosis and personalized therapy options for blastoma. Alfa Cytology is committed to solving various problems in the field of blastoma vaccine development and has in-depth and extensive experience in preclinical services. If you are interested in our service, please contact us for more details.
Reference